Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Activating TP53 by Dual Inhibition of MDMX and MDM2

Ulrich G. Steidl, MD PhD

Blood (2019) 134 (Supplement_1): SCI-14.

https://doi.org/10.1182/blood-2019-121097

Published: 2019

Journal Articles

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

David A Sallman, MD, Uma Borate, MD, Elizabeth H. Cull, MD, William B. Donnellan, MD, Rami S. Komrokji, MD, Ulrich G. Steidl, MD PhD, Maria M Corvez, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amit Verma, MD

Blood (2018) 132 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2018-99-118780

Published: 2018

Journal Articles

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Andrei R. Shustov, MD, Amitkumar Mehta, MD, Lubomir Sokol, MD PhD, Luis A. Carvajal, PhD, Vincent Guerlavais, PhD, Manoj Samant, PhD, Narayana Narasimhan, PhD, David Sutton, BSc, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Ronald Korn, MD PhD

Blood (2018) 132 (Supplement 1): 5348.

https://doi.org/10.1182/blood-2018-99-119489

Published: 2018

Journal Articles

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Raphael Koch, MD, Amanda L Christie, BS, Noriaki Yoshida, MD PhD, Samuel Y. Ng, MDPhD, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Steven M. Horwitz, MD, Eric Jacobsen, MD, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, PhD, D. Allan Annis, Manuel A. Aivado, MD PhD, David M. Weinstock, MD

Blood (2017) 130 (Supplement 1): 571.

https://doi.org/10.1182/blood.V130.Suppl_1.571.571

Published: 2017

Journal Articles

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Luis A. Carvajal, PhD, Daniela Ben-Neriah, B.S, Adrien Senecal, PhD, Lumie Bernard, M.S, Swathi-Rao Narayanagari, M.S, Charles Kenworthy, B.S, Victor Thiruthuvanathan, M.S, Vincent Guerlavais, PhD, D. Allen Annis, PhD, Boris Bartholdy, PhD, Britta Will, PhD, Jesus Anampa, MD, Ioannis Mantzaris, MD, Manuel A. Aivado, MD PhD, Robert H Singer, PhD, Robert Coleman, PhD, Amit Verma, MD, Ulrich G. Steidl, MDPhD

Blood (2017) 130 (Supplement 1): 795.

https://doi.org/10.1182/blood.V130.Suppl_1.795.795

Published: 2017

Journal Articles

Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL

Fabio Brocco, Hanneke ter Burg, Stacey Fernandes, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Francesco Forconi, MD DM, PhD FRCPath, Rachel M Guerra, Gregory Bird, Loren D Walensky, Jennifer R. Brown, MD PhD, Arnon P Kater, Eric Eldering

Blood (2017) 130 (Supplement 1): 262.

https://doi.org/10.1182/blood.V130.Suppl_1.262.262

Published: 2017

Journal Articles

Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma

Mariateresa Fulciniti, Charles Y. Lin, Mehmet K Samur, PhD, Matthew Lawlor, Kenneth C Anderson, James E. Bradner, MD, Nikhil C. Munshi, MD

Blood (2015) 126 (23): 838.

https://doi.org/10.1182/blood.V126.23.838.838

Published: 2015

Journal Articles

A Stapled BIM BH3 Helix Restores Apoptosis In Bim -Null Mantle Cell Lymphoma

Samuel G Katz, MD, PhD, James L Labelle, MD, PhD, Marina Godes, Jill Fisher, Gregory H. Bird, PhD, Loren D. Walensky, MD, PhD

Blood (2010) 116 (21): 437.

https://doi.org/10.1182/blood.V116.21.437.437

Published: 2010

Journal Articles

A Stapled p53 Helix Targets HDMX to Overcome Nutlin-3 Resistance and Reactivate the p53 Tumor Suppressor Pathway in Cancer

Federico Bernal, Ph.D., Mark Wade, Ph.D., Amy M. Silverstein, Gregory L. Verdine, Ph.D., Geoffrey M. Wahl, Ph.D., Loren D. Walensky, M.D., Ph.D.

Blood (2008) 112 (11): 2645.

https://doi.org/10.1182/blood.V112.11.2645.2645

Published: 2008

Journal Articles

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

Rosana Kapeller, Jiawen Han, Kaiming Sun, Pranoti Gangurde, Nori Kawahata, Matt Iadanza, Vincent Guerlevais, Jim Horstick, Justin Noehre, Allen Annis, Larry Licklider, Huw M. Nash, Andrew Kung, Tomi K. Sawyer

Blood (2008) 112 (11): 2929.

https://doi.org/10.1182/blood.V112.11.2929.2929

Published: 2008

Journal Articles

A Stapled BIM BH3 Helix Overcomes the MCL-1-Mediated Apoptotic Blockade of Refractory Hematologic Cancers

James L. Labelle, MD, PhD, Chelsea E. Lawrence, Gregory H. Bird, Ph.D., Loren D. Walensky, M.D., Ph.D.

Blood (2008) 112 (11): 862.

https://doi.org/10.1182/blood.V112.11.862.862

Published: 2008

Journal Articles

Direct Inhibition of the Notch Transactivation Complex with Synthetic Constrained Peptides in T-Cell Acute Lymphoblastic Leukemia.

Raymond Moellering, BA, Melanie Cornejo, B.A., Jennifer Rocknik, B.A., Michael Hancock, Ph.D., Christina DelBianco, Ph.D., Stephen Blacklow, M.D., Ph.D., Gary Gilliland, M.D., Ph.D., Gregory Verdine, Ph.D., James Bradner, M.D.

Blood (2007) 110 (11): 2819.

https://doi.org/10.1182/blood.V110.11.2819.2819

Published: 2007

Journal Articles

Selective Targeting of the p53-hDM2 Interaction Using Hydrocarbon-Stapled p53 Peptides.

Federico Bernal, PhD, Loren D. Walensky, MD,PhD, Andrew F. Tyler, Stanley J. Korsmeyer, MD, Gregory L. Verdine, PhD

Blood (2006) 108 (11): 525.

https://doi.org/10.1182/blood.V108.11.525.525

Published: 2006

Journal Articles

Anti-Leukemic Potency of Stapled BH3 Helices Correlates with Their Capacity for Bifunctional Activation of Apoptotic Pathways.

Loren D. Walensky, MD, PhD, Kenneth Pitter, Joel G. Morash, Gregory L. Verdine, PhD, Stanley J. Korsmeyer, MD

Blood (2006) 108 (11): 711.

https://doi.org/10.1182/blood.V108.11.711.711

Published: 2006

NARROW

Activating TP53 by Dual Inhibition of MDMX and MDM2

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL

Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma

A Stapled BIM BH3 Helix Restores Apoptosis In Bim -Null Mantle Cell Lymphoma

A Stapled p53 Helix Targets HDMX to Overcome Nutlin-3 Resistance and Reactivate the p53 Tumor Suppressor Pathway in Cancer

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

A Stapled BIM BH3 Helix Overcomes the MCL-1-Mediated Apoptotic Blockade of Refractory Hematologic Cancers

Direct Inhibition of the Notch Transactivation Complex with Synthetic Constrained Peptides in T-Cell Acute Lymphoblastic Leukemia.

Selective Targeting of the p53-hDM2 Interaction Using Hydrocarbon-Stapled p53 Peptides.

Anti-Leukemic Potency of Stapled BH3 Helices Correlates with Their Capacity for Bifunctional Activation of Apoptotic Pathways.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only